• OPEN AN ACCOUNT
Indian Indices
Nifty
24,718.60 -169.60
(-0.68%)
Sensex
81,118.60 -573.38
( -0.70%)
Bank Nifty
55,527.35 -555.20
( -0.99%)
Nifty IT
38,469.25 8.95
( 0.02%)
Global Indices
Nasdaq
42,214.73 -773.90
(-1.80%)
Dow Jones
5,997.34 -68.92
(-1.14%)
Hang Seng
37,801.43 -371.66
(-0.97%)
Nikkei 225
8,850.63 -34.29
(-0.39%)
Forex
USD-INR
85.55 0.07
(0.08%)
EUR-INR
98.89 0.98
(1.00%)
GBP-INR
116.24 0.70
(0.61%)
JPY-INR
0.60 0.01
(0.86%)

EQUITY - MARKET SCREENER

Enfuse Solutions Ltd
Industry :  Computers - Software - Medium / Small
BSE Code
ISIN Demat
Book Value()
92697
INE0S3X01014
39.6012478
NSE Symbol
P/E(TTM)
Mar.Cap( Cr.)
ENFUSE
68.12
221.19
EPS(TTM)
Face Value()
Div & Yield %
3.67
10
0
 

Cipla receives USFDA approval for Protein-bound Paclitaxel for Injectable Suspension
Apr 11,2025
Cipla has received final approval from the United States Food and Drug Administration (USFDA) for the Abbreviated New Drug Application (ANDA) submitted for Paclitaxel Protein-bound Particles for Injectable Suspension (albumin-bound), 100 mg/vial, Single-Dose Vial (Protein-bound Paclitaxel) on 10 April 2025.

Cipla's Protein-bound Paclitaxel is an AB-rated generic therapeutic equivalent version of Bristol Myers Squibb's Abraxane® for Injectable Suspension 100 mg/vial. Protein-bound Paclitaxel is indicated for the treatment of metastatic breast cancer, locally advanced or metastatic non-small cell lung cancer (‘NSCLC') and metastatic adenocarcinoma of the pancreas. The product is expected to be launched in H1 FY 2025-26 in the United States of America.